We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections in Asia
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an exclusive license agreement for the Indian market with Venus Remedies Ltd, an Indian pharmaceutical company,…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Grant to develop first-in-class antimicrobial drug targeting multi-drug-resistant bacteria
Latest News
Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired drug-resistant…
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Grant to develop first-in-class antimicrobial drug targeting multi-drug-resistant…
First NCFB patient dosed in Phase IIa study of RESP-X
Potential first-in-class anti-virulence antibody drug to reduce the frequency of…
Infex invites you to Alderley Park’s 10th Anniversary SciTech Extravaganza
Come and join us in Glasshouse at Alderley Park for an interactive and inspiring day of…
Infex to present RESP-X Phase I data at ERS Congress
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of…
Infex strengthens its senior leadership team
Appointment of Director of Clinical Programmes and changes to senior management team
Infex webinar – broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the company's…
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Infex Therapeutics, a leading anti-infectives specialist, welcomes the UK government’s…